Anish Parmar
Postdoctoral Research Associate
University of Liverpool
UK
Dr. Anish Parmar is a Postdoctoral Research Associate at the University of Liverpool, working within Dr. Ishwar Singh. Together, their research group strives to discover and develop unique compounds for improving and saving lives currently lost due to antimicrobial resistance. We will achieve this by refreshing the antimicrobial pipeline with simpler, safer, effective innovative molecules capable of tackling resistant bacterial infection.
He obtained his PhD from the University of Lincoln, where he received a Research Excellence Award on his PhD work on simplified Teixobactin. He graduated from the University of Leicester with his Bachelor’s and Master’s degree in Pharmaceutical Chemistry (2009) and Cancer Chemistry (2010) respectively.
Outside work he has also played international cricket for Kenya (juniors team) and enjoys watching and playing various sports such as Football and tennis.
H1 - Design, synthesis and biological evaluation of novel teixobactin analogues.
Antimicrobial resistance is one of the greatest emerging threats making this a major public health concern. In the past 40 years, only two new classes antibiotics have reached clinic. There is an urgent need for new classes of antibiotics to fight rapid development of resistance in bacteria. The discovery of the new class of antibiotic in 2015 is regarded as a game-changer in the race for unearthing novel antibiotics. Teixobactin is a cyclic depsipeptide, which kills Gram-positive bacteria, including multidrug-resistant bacteria, without detectable resistance. Teixobactin binds to highly conserved parts of bacterial specific lipids such as lipid II and lipid III. Teixobactin attacks the bacteria on multiple fronts and operates by unique modes of action, bacteria are less likely to develop resistance. At the University of Liverpool, we have created a novel design and efficient synthesis utilising affordable building blocks to generate synthetic libraries of teixobactin analogues in to understand the therapeutic potential of teixobactins.